Estrogen-independent role of ERα in ovarian cancer progression induced by leptin/Ob-Rb axis.
Cell invasion
Estradiol
Estrogen receptor
Leptin
Ovarian cancer
Journal
Molecular and cellular biochemistry
ISSN: 1573-4919
Titre abrégé: Mol Cell Biochem
Pays: Netherlands
ID NLM: 0364456
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
22
10
2018
accepted:
02
05
2019
pubmed:
12
5
2019
medline:
19
7
2019
entrez:
12
5
2019
Statut:
ppublish
Résumé
Leptin induces ovarian cancer cell invasion via overexpression of MMP7, MMP9, and upA. In addition, the key role of ERα in leptin-increased cell growth was indicated. However, the influence of ER on leptin-mediated cell invasion remains still unknown. The present study was designed to evaluate the E2-independent effect of ERα/β on leptin-mediated cell invasion and cell proliferation in ovarian cancer. We utilized SKOV3 cancer (expressing OB-Rb and ERα/β, insensitive to estrogen) and OVCAR3 (expressing OB-Rb) cell lines to show the involvement of ER in leptin-mediated effects in an E2-independent manner. MTT, BrdU, and BD matrigel invasion assays were applied to analyze cell growth, proliferation, and invasion. The siRNA approach was used to confirm the role of ERα/β in leptin effects. Moreover, western blotting and Real-time PCR were employed to detect the OB-Rb, ER, MMP9/7, and upA proteins and mRNAs. Leptin, in the absence of E2, increased ERα expression in SKOV3 cells, which was attenuated using knockdown of OB-Rb gene by siRNA. The effect of leptin on the cell growth was promoted in the presence of PPT, but not in the presence of DNP and E2, which was lost when OB-Rb siRNA was transfected. Furthermore, ERα gene silencing and/or pre-incubation with ER antagonist (ICI 182,780, 10 nM) significantly reduced cell invasion and MMP9 expression stimulated by leptin. In conclusion, our findings demonstrated that ERα, but not ERβ, is involved in leptin-induced ovarian cancer in an E2-independent manner, providing new evidence for cancer progression in obesity-associated ovarian cancer.
Identifiants
pubmed: 31077012
doi: 10.1007/s11010-019-03544-5
pii: 10.1007/s11010-019-03544-5
doi:
Substances chimiques
ESR1 protein, human
0
Estrogen Receptor alpha
0
LEP protein, human
0
Leptin
0
Neoplasm Proteins
0
Receptors, Leptin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-217Références
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5722-7
pubmed: 10318951
Mol Hum Reprod. 1999 Aug;5(8):708-13
pubmed: 10421796
Obstet Gynecol. 2000 Sep;96(3):417-21
pubmed: 10960636
J Biol Chem. 2001 Oct 5;276(40):36869-72
pubmed: 11459850
Int J Obes Relat Metab Disord. 2002 Nov;26(11):1407-33
pubmed: 12439643
J Biol Chem. 2003 Aug 1;278(31):28668-76
pubmed: 12734209
J Biol Chem. 2004 May 7;279(19):19908-15
pubmed: 14985328
Mol Interv. 2003 Aug;3(5):281-92
pubmed: 14993442
Gynecol Oncol. 2004 Jul;94(1):25-32
pubmed: 15262115
Clin Cancer Res. 2004 Oct 1;10(19):6466-75
pubmed: 15475434
Cancer Lett. 2006 Jan 18;231(2):151-7
pubmed: 16399219
Philos Trans R Soc Lond B Biol Sci. 2006 Jul 29;361(1471):1237-49
pubmed: 16815801
Int J Oncol. 2007 Jun;30(6):1499-509
pubmed: 17487372
Cancer. 2009 Feb 15;115(4):812-22
pubmed: 19127552
Mol Cancer. 2009 Sep 18;8:74
pubmed: 19765303
Annu Rev Med. 2010;61:301-16
pubmed: 19824817
Int J Cancer. 2010 Jul 1;127(1):55-66
pubmed: 19876927
Endocr Relat Cancer. 2010 Apr 21;17(2):373-82
pubmed: 20410173
BMC Cancer. 2010 Jun 22;10:320
pubmed: 20569445
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Carcinogenesis. 2011 Apr;32(4):589-96
pubmed: 21173433
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
J Cell Biochem. 2012 Apr;113(4):1323-32
pubmed: 22135239
Endocrinology. 2012 Apr;153(4):1593-602
pubmed: 22416079
Biomed Pharmacother. 2013 Feb;67(1):22-30
pubmed: 23199901
Clin Cancer Res. 2013 Apr 15;19(8):1926-32
pubmed: 23355630
Cytokine. 2013 Mar;61(3):876-84
pubmed: 23357303
Biochim Biophys Acta. 2013 Oct;1831(10):1499-508
pubmed: 23470257
FEBS J. 2014 Feb;281(3):927-42
pubmed: 24283290
J Endocrinol. 2014 May 12;221(2):325-36
pubmed: 24819599
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
Mol Med Rep. 2014 Nov;10(5):2433-40
pubmed: 25216292
Ecancermedicalscience. 2014 Sep 25;8:465
pubmed: 25371706
Life Sci. 2015 Jan 15;121:10-5
pubmed: 25433128
Oncotarget. 2015 Aug 28;6(25):21100-19
pubmed: 26053184
Breast Cancer Res. 2015 Aug 19;17:112
pubmed: 26286584
PLoS One. 2016 Mar 16;11(3):e0151455
pubmed: 26982332
Recent Results Cancer Res. 2016;208:155-176
pubmed: 27909907
Clin Cancer Res. 2017 Jul 15;23(14):3802-3812
pubmed: 28073843
Cell Signal. 2017 Apr;32:104-114
pubmed: 28104444
Arch Med Sci. 2017 Feb 1;13(1):228-235
pubmed: 28144276
CA Cancer J Clin. 2017 Sep;67(5):378-397
pubmed: 28763097
BMC Cancer. 2017 Aug 31;17(1):606
pubmed: 28859612
J Cell Biochem. 2018 Feb;119(2):2333-2344
pubmed: 28885729
Cytokine Growth Factor Rev. 2017 Dec;38:80-97
pubmed: 29158066
Oncotarget. 2017 Nov 25;8(65):109417-109435
pubmed: 29312618
BMC Cancer. 2018 Jan 25;18(1):99
pubmed: 29370782
Int J Cancer. 1983 Oct 15;32(4):413-22
pubmed: 6311758
J Steroid Biochem Mol Biol. 1995 Dec;55(3-4):279-89
pubmed: 8541224
J Clin Endocrinol Metab. 1998 Mar;83(3):1025-8
pubmed: 9506768
Cancer Res. 1998 Dec 1;58(23):5367-73
pubmed: 9850067